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Background: We investigated whether routine elective irradiation of a clinically negative inguinal node (IGN) is
necessary for patients with locally advanced distal rectal cancer and anal canal invasion (ACI).
Methods: We reviewed retrospectively 1,246 patients with locally advanced rectal adenocarcinoma managed using
preoperative or postoperative chemoradiotherapy and radical surgery between 2001 and 2011. The patients’ IGN
was clinically negative at presentation and IGN irradiation was not performed. ACI was defined as the lower edge
of the tumor being within 3 cm of the anal verge. Patients were divided into two groups, those with ACI (n = 189,
15.2%) and without ACI (n = 1,057, 84.8%).
Results: The follow-up period was a median of 66 months (range, 3–142 months). Among the 1,246 patients, 10
developed IGN recurrence; 7 with ACI and 3 without ACI. The actuarial IGN recurrence rate at 5 years was 0.7%;
3.5% and 0.2% in patients with and without ACI, respectively (p < 0.001). Isolated IGN recurrence occurred in three
patients, all of whom had ACI tumors. These three patients received curative intent local treatments, and one was alive
with no evidence of disease 10 years after IGN recurrence. Salvage treatments in the other two patients controlled
successfully the IGN recurrence for >5 years, but they developed second malignancy or pelvic and distant recurrences.
Seven patients with non-isolated IGN recurrence died of disease at 5–22 months after IGN recurrence.
Conclusion: The low IGN recurrence rate even with ACI and the feasibility of salvage of isolated IGN recurrence
indicated that routine elective IGN irradiation is not necessary for rectal cancer with ACI.
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The lymphatic drainage from the rectum occurs preferen-
tially in a proximal direction. The lymphatic system sup-
plies the mesenteric and para-aortic nodes through the
perirectal and pelvic lymphatic vessels. However, when a
distal rectal tumor invades the anal canal, the lymphatic
system drains in another direction to the inguinal nodes
(IGN), as observed in primary anal cancer, through the
perirectal, perianal and pudendal lymphatics [1].* Correspondence: radiopiakim@hanmail.net
†Equal contributors
2Proton Therapy Center, Research Institute and Hospital, National Cancer
Center, Goyang, Korea
3Center for Colorectal Cancer, Research Institute and Hospital, National
Cancer Center, Goyang, Korea
Full list of author information is available at the end of the article
© 2014 Yeo et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Radiation therapy (RT) is an important constituent of
multi-modality management recommended for locally ad-
vanced (stage II or III) rectal cancer [2]. Preoperative or
postoperative RT reduces local disease recurrence and the
former improves resectability and sphincter preservation
by downstaging or downsizing the tumor [3]. Conven-
tional RT fields for rectal cancer encompass regional lym-
phatics which do not contain IGN [4], whereas standard
RT fields for anal cancer involve IGN because the risk of
local recurrence is high in this region without elective
treatment [5]. Thus, for a subset of rectal cancer patients
with anal canal invasion (ACI) and with potential lymph-
atic drainage to IGN, whether RT fields should be ex-
tended to involve IGN basins remains questionable [5].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cer with clinically negative IGN at presentation has been
no irradiation of IGN, regardless of tumor location. To
determine the requirement for routine elective IGN ir-
radiation for patients with distal rectal cancer and ACI,
we investigated the failure patterns and salvage feasibility
regarding IGN recurrence and conducted a comparison
between rectal tumors with and without ACI.Methods
Patients
A total of 1,246 patients with locally advanced rectal
cancer treated with preoperative or postoperative che-
moradiotherapy (CRT) and radical surgery between 2001
and 2011 at the National Cancer Center (Goyang, Korea)
were reviewed retrospectively. The patients had histolog-
ically confirmed rectal adenocarcinoma and no evidence of
distant metastasis, including IGN, at the time of initial
workup and surgery. Concurrent CRT was administered
preoperatively (cT3–4) or postoperatively (pT3–4 or pN+)
in 877 (70.4%) and 369 (29.6%) patients, respectively. Since
the introduction of preoperative CRT at our institution in
October 2001, routine treatment for clinically staged T3–4
rectal cancer located at the mid-to-low rectum (≤9 cm from
the anal verge) has gradually changed from postoperative to
preoperative CRT. During and after the transition period,
upfront surgery with postoperative CRT was performed
routinely for upper rectal cancer, and for mid-to-low rectal
cancer, it was determined by the preferences of patients or
attending physicians.
Pretreatment workups for clinical staging included digital
rectal examination, complete blood count, liver function
tests, serum carcinoembryonic antigen tests, video colonos-
copy, chest radiography and computed tomography (CT)
scanning of the abdomen and pelvis with or without trans-
rectal ultrasonography and pelvic magnetic resonance im-
aging (MRI). 18F-deoxyfluoroglucose positron emission
tomography-CT was performed as required. Clinically posi-
tive lymph node involvement was defined as a lymph node
with the smallest diameter of 0.5 cm, observed on CT or
MRI. All stages were determined according to the Ameri-
can Joint Committee on Cancer Staging System, 7th edi-
tion [4]. Anal canal involvement (ACI) was defined when
the lower edge of the tumor was within 3 cm from the
anal verge on colonoscopy or digital rectal examination.
Digital rectal examination for all patients in the present
study was performed by one experienced radiation oncolo-
gist (Dr. DY Kim). Patients were grouped and compared
according to the existence of ACI; 189 (15.2%) with ACI
and 1,057 (84.8%) without ACI. All patients provided
written informed consent before treatments and the study
was performed in accordance with the guidelines of our
Institutional Review Board of the National Cancer Center.Treatments
Radiotherapy was delivered to the whole pelvis at a dose
of 45 Gy in 25 fractions, followed by a 5.4-Gy boost in
three fractions within 6 weeks. All patients underwent
CT simulation for three-dimensional conformal plan-
ning, and a three-field treatment plan used a 6-MV pho-
ton posterior-anterior field and 15-MV photon-opposed
lateral beams. The prescription dose was specified at the
isocenter of the planning target volume. The initial radi-
ation field encompassed the gross tumor and mesorectum
(preoperative CRT) or tumor bed (postoperative CRT),
presacral space, the entire sacral hollow and the regional
lymphatics, including the perirectal, internal iliac, presa-
cral and distal common iliac lymphatics. The superior
border was placed at L5/S1 and the inferior border at > 3
cm caudal to the gross tumor or tumor bed. The boost
field included the gross tumor volume and mesorectum
(preoperative CRT) or tumor bed (postoperative CRT),
with ≥ 2 cm margin in all directions.
Chemotherapy administered concurrently with RT used
one of the following regimens: fluoropyrimidine, irinote-
can, or an oxaliplatin-based regimen. Patients underwent
radical proctectomy, including high ligation of the inferior
mesenteric vessels and total mesorectal excision. The
interval between preoperative CRT and surgery was 4–8
weeks, and 3–8 weeks between surgery and postoperative
CRT. Postoperative chemotherapy was initiated 3–6 weeks
after surgery or postoperative CRT, using fluoropyrimidine
or an oxaliplatin-based regimen.
Evaluation
All patients underwent standardized follow-up, consisting
of physical examination, complete blood count, liver func-
tion tests, serum carcinoembryonic antigen tests and chest
radiography every 3 months for the first 2 years and every
6 months thereafter, as well as abdominopelvic CT every 6
months. Colonoscopic examinations were performed 1
year postoperatively and then at 2-year intervals. Recur-
rence was determined based on clinical, radiological or
histological findings. Radiological evidence involved serial
radiological examinations showing progressive mass
growth, including abnormally high uptake on 18F-deoxy-
fluoroglucose positron emission tomography.
Analysis
Intergroup comparisons regarding patient, tumor and
treatment characteristics were conducted using the chi-
square test, Fisher’s exact test, linear-by-linear association,
or t-test, depending on the nature of the data. Multivariate
logistic regression was conducted to determine parameters
that are related with IGN recurrence. Actuarial IGN recur-
rence rate was estimated using the Kaplan-Meier method
and the significance of differences was assessed with the
log-rank test. The level of statistical significance was set at
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tical analyses were performed using the SPSS software (ver-
sion 14.0; SPSS Inc., Chicago, IL, USA).
Results
Patients
Patient, tumor and treatment characteristics according
to existence of ACI in all 1,246 patients are listed in
Table 1. Distance from anal verge to distal tumor end
was a median of 2.0 cm (range, 0–3.0 cm) in the ACI
group and 7.0 cm (range, 3.5–13.0 cm) in the non-ACI
group. Female gender and a high histological grade were
more frequent in rectal tumors with ACI. Preoperative
CRT and irinotecan or an oxaliplatin-based regimen were
prescribed more frequently for rectal tumors with ACI.
Abdominoperineal resection was performed in 66.7% of
rectal tumors with ACI. The follow-up period of all 1,246Table 1 Comparison of characteristics according to ACI in all
Age (yr) Mean ± SD
Gender Male
Female
Distance from anal verge (cm) Mean ± SD
Histological grade* Low
High
(Not specified = 28)
Clinical stage cStage II
cStage III




CRT timing Preoperative CRT
Postoperative CRT





CRM Negative (>0.1 cm)
Positive (≤0.1 cm)
(Not specified = 11)
Postoperative chemotherapy Yes
No†
Abbreviations: ACI anal canal invasion, SD standard deviation, CRT chemoradiotherap
*Evaluated by pretreatment diagnostic biopsy. Low indicates well or moderately dif
cell carcinoma.
†Including patients who did not finish the planned chemotherapy.
‡Chi-square test, linear-by-linear association, or t-test.patients was a median of 66 months (range, 3–142
months). This was not different in 189 with ACI vs. 1,057
without ACI; 71.4 ± 35.4 vs. 68.8 ± 33.1 months, respect-
ively (p = 0.333).
Patterns of IGN recurrence
Of 1,246 patients, 10 developed IGN recurrence; 7 with
ACI and 3 without ACI. Characteristics of the 10 pa-
tients are listed in Table 2. All 10 patients had disease in
the regional pelvic lymph nodes initially and 2 had mu-
cinous or signet ring cell carcinoma. Distance from the
anal verge to the distal tumor end was a median of 1 cm
(range, 0–2.5 cm) in patients with ACI and ranged from
5–10 cm in patients without ACI. Patients’ characteris-
tics were compared according to IGN recurrence
(Table 3). Significant difference existed in the rate of
sphincter-sparing surgery, in addition to tumor distancepatients
With ACI (n = 192) Without ACI (n = 1,054) p-value‡
57.6 ± 11.3 58.2 ± 10.8 0.462
114 (59.4) 718 (68.1) 0.018
78 (40.6) 336 (31.9)
2.0 ± 0.9 6.9 ± 2.1 <0.001
171 (90.0) 989 (96.2) <0.001
19 (10.0) 39 (3.8)
42 (21.9) 213 (20.2) 0.599
150 (78.1) 841 (79.8)
26 (13.5) 104 (9.9) 0.001
47 (24.5) 176 (16.7)
54 (28.1) 299 (28.4)
65 (33.9) 475 (45.1)
168 (87.5) 709 (67.3) <0.001
24 (12.5) 345 (32.7)
166 (86.5) 960 (91.8) 0.018
26 (13.5) 86 (8.2)
64 (33.3) 1,016 (96.4) <0.001
128 (66.7) 38 (3.6)
154 (80.2) 890 (85.3) 0.071
38 (19.8) 153 (14.7)
175 (91.1) 962 (91.3) 0.955
17 (8.9) 92 (8.7)
y, CRM circumferential resection margin.
ferentiated; high indicates poorly differentiated, mucinous, or signet ring
Table 2 Characteristics of patients with IGN recurrence
No ACI Gender/Age cStage pStage/ypStage Hisological grade† Surgery
1 Yes (1.0)* F/38 cT3N1M0 ypT2N1bM0 Low LAR
2 Yes (1.5) F/57 cT4N1M0 ypT0N0M0 High APR
3 Yes (0.0) M/59 cT3N1M0 ypT4bN1bM0 Low APR
4 Yes (2.5) M/55 cT3N2M0 ypT3N0M0 Low APR
5 Yes (0.5) M/50 cT3N2M0 ypT2N0M0 Low APR
6 Yes (0.0) M/58 cT3N1M0 ypT4bN2aM0 Low APR
7 Yes (2.0) F/58 cT3N2M0 pT3N2aM0 High APR
8 No (5.0) M/57 cT3N2M0 pT3N2aM0 Low LAR
9 No (9.0) M/52 cT3N2M0 pT3N2bM0 Low LAR
10 No (10.0) M/54 cT3N2M0 pT3N2aM0 Low LAR
Abbreviations: IGN inguinal node, ACI anal canal invasion, LAR low anterior resection, APR abdominoperineal resection.
*Data in parenthesis are the distance (cm) from the anal verge to the distal end of the tumor.
†Evaluated by pretreatment diagnostic biopsy. Low indicates well or moderately differentiated; high indicates poorly differentiated, mucinous, or signet ring cell carcinoma.
Table 3 Comparison of characteristics according to IGN recurrence in all patients
With IGN recurrence (n = 10) Without IGN recurrence (n = 1,236) p-value‡
Age (yr) Mean ± SD 53.8 ± 6.3 58.1 ± 10.9 0.057
Gender Male 7 (0.8) 825 (99.2) 1.000
Female 3 (0.7) 411 (99.3)
Distance from anal verge (cm) Mean ± SD 3.4 ± 3.8 6.2 ± 2.6 0.046
Histological grade* Low 8 (0.7) 1152 (99.3) 0.078
High 2 (3.4) 56 (96.6)
(Not specified = 28)
Clinical stage cStage II 0 255 (100) 0.229
cStage III 10 (1.0) 981 (99.0)
Pathological stage ypStage 0 1 (0.8) 129 (99.2) 0.267
ypStage I 1 (0.4) 222 (99.6)
pStage II/ypStage II 1 (0.3) 352 (99.7)
pStage III/ypStage III 7 (1.3) 533 (98.7)
CRT timing Preoperative CRT 6 (0.7) 871 (99.3) 0.494
Postoperative CRT 4 (1.1) 365 (98.9)
Concurrent chemotherapy Fluoropyrimidine alone 10 (0.9) 1116 (99.1) 0.613
Irinotecan or oxaliplatin-based 0 112 (100)
(Not specified = 8)
Surgery Sphincter-sparing surgery 4 (0.4) 1076 (99.6) 0.001
Abdominoperineal resection 6 (3.6) 160 (96.4)
CRM Negative (>0.1 cm) 9 (0.9) 1035 (99.1) 1.000
Positive (≤0.1 cm) 1 (0.5) 190 (99.5)
(Not specified = 11)
Postoperative chemotherapy Yes 10 (0.9) 1127 (99.1) 1.000
No† 0 109 (100)
Abbreviations: IGN inguinal node, SD standard deviation, CRT chemoradiotherapy, CRM circumferential resection margin.
*Evaluated by pretreatment diagnostic biopsy. Low indicates well or moderately differentiated; high indicates poorly differentiated, mucinous, or signet ring
cell carcinoma.
†Including patients who did not finish the planned chemotherapy.
‡Fisher’s exact test, linear-by-linear association, or t-test.
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maintained its statistical significance in the multivariate
analysis (≤3 cm vs. > 3 cm; odds ratio 7.287, 95% confi-
dence interval 1.102 – 48.171, p = 0.039).
Actuarial IGN recurrence at 5 years was 0.7%. When
estimated separately in patients with and without ACI,
the rates were 3.5% and 0.2%, respectively (p < 0.001).
The disease-free interval until IGN recurrence was a
median of 29 months (range, 8–105 months) from initial
management; 27.9 ± 16.5 vs. 50.3 ± 49.1 months with and
without ACI, respectively (p = 0.513).
Isolated IGN recurrence occurred in three patients,
all of whom had tumors with ACI. The other seven pa-
tients showed additional synchronous recurrences; both
pelvic recurrence and distant metastasis in four, distant
metastasis without pelvic recurrence in two, and one
showed pelvic recurrence first at 93 months; this patient
subsequently (1 year later) developed IGN recurrence
and peritoneal seeding.
Salvage outcomes
Salvage outcomes of the 10 patients with IGN recurrence
are described in Table 4. Among the seven patients with
ACI, isolated IGN recurrence occurred in three and IGN
recurrence combined with pelvic recurrence and/or distant
metastasis in four. All three patients with isolated IGN re-
currence received curative intent local treatments. Concur-
rent CRT was performed in two patients (patients #1 and
2) and surgical excision followed by concurrent CRT in
one (patient #3). RT target included only the involved
groin region and prescribed total RT doses were 63, 72,
and 54 Gy, respectively, in the three patients. Status at the
last follow-up showed no evidence of disease for 10 years
after salvage treatment in one patient (patient #1). Salvage










4 No Brain Bilateral
5 No LPN, PAN Bilateral
6 No LPN, PAN Unilateral
7 No PAN Unilateral
8 No Tumor bed, lung Unilateral
9 No LPN, PAN Bilateral
10 No LPN, seeding Unilateral
Abbreviations: IGN inguinal node, LPN lateral pelvic node, PAN para-aortic node, NED
*IGN recurrence was successfully salvaged with concurrent CRT, but endometrial ca
metastasis and peritoneal seeding causing death.
†Recurrence developed initially in the tumor bed at 93 months and non-isolated IGthe IGN recurrence for >5 years, but second malignancy
or disease recurrence occurred; one (patient #2) devel-
oped endometrial cancer 31 months after salvage result-
ing in death, and the other (patient #3) is alive but
developed lung metastasis, pelvic and retroperitoneal
lymph node recurrences 38 months after salvage. Four
patients (patients #4–7) with ACI and non-isolated IGN
recurrence received palliative chemotherapy but died of
the disease at 5–22 months after IGN recurrence.
Non-isolated IGN recurrence occurred in all three pa-
tients without ACI. They received palliative CRT, chemo-
therapy, pelvic exenteration or supportive care, but died of
rectal cancer at 8, 11, and 20 months after IGN recurrence.
Discussion
In the 2009 consensus report of the Radiation Therapy
Oncology Group on the definition of clinical target vol-
ume for anorectal cancer, the panel group was divided as
to whether elective irradiation of the IGN region in rec-
tal adenocarcinomas with ACI is necessary [5]. So far,
few studies have focused on the optimal RT fields for
rectal cancer with ACI. Taylor et al. [6] assessed IGN re-
currence rates in rectal cancer with ACI after preopera-
tive or postoperative pelvic RT, of which the treatment
field did not include the groin region. The 5-year IGN
recurrence rate was 4% (6 of 184 patients) in rectal can-
cer with ACI. In other patients with rectal tumors and
without ACI, the 5-year IGN recurrence rate was < 1%
(3 of 350 patients). Based on their observation of low re-
currence rates in IGN and the historical reports of groin
RT-related morbidities, the authors insisted against rou-
tine elective groin irradiation for rectal cancer with ACI.
The present study analyzed a larger number of patients
and reported similar IGN recurrence rates. The 5-year















no evidence of disease, AWD alive with disease, DWD dead with disease.
ncer developed 31 months after IGN recurrence that progressed to lung
N recurrence occurred 1 year later.
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ACI. These outcomes support the insistence that routine
irradiation of clinically negative IGN in rectal cancers
with ACI is difficult to be justified.
In contrast, Lee et al. [7] reported that elective irradi-
ation of IGN is highly effective in controlling its subclin-
ical disease with minimal morbidity. They performed
elective IGN irradiation in patients with pelvic tumors
suspected to be at significant (>10%) risk of harboring oc-
cult subclinical disease in IGN. Primary tumor sites were
heterogeneous, and included the cervix, vagina, rectum
(with ACI), anus, vulva, urethra, and penis. Of 164 pa-
tients treated, 105 (rectum= 22) were eligible for analysis
of IGN control. IGN recurrence was not detected in rectal
cancer patients but developed in three patients with vulvar
cancer and one with cervical cancer; the IGN recurrence
rate was 4% at 2 years. However, the authors excluded
seven patients with IGN recurrence (primary not speci-
fied) from IGN control analysis because the pelvic recur-
rence preceded their IGN recurrences. They thought that
in this situation, IGN recurrence occurred by reseeding
from the pelvic recurrence, which could cause bias in the
analysis. In the present study, pelvic recurrence was
present with or before IGN recurrence in half (5/10) of
the patients with IGN recurrence. In the lower rectum,
the difference in local anatomy (limited visualization and
access) and surgical technique applied (abdominoperineal
resection) lead to more frequent local pelvic recurrences
compared with in the mid or upper rectum [8,9]. When
pelvic recurrence develops, interruption of ascending
lymphatic drain due to a previous lymphadenectomy
causes retrograde lymphatic flow into the IGN [10]. If
these cases were excluded from our analysis using the
same approach, estimated IGN recurrence risk in patients
with ACI would be further decreased.
Pelvic recurrence and/or distant metastasis was de-
tected synchronously with IGN recurrence in rectal tu-
mors without ACI, whereas isolated IGN recurrence
developed only in rectal tumors with ACI, both in the
present study and that by Taylor et al. [6]. Salvage ther-
apy for isolated IGN recurrence appeared to yield dur-
able control in the IGN region. Taylor et al. [6] treated
three rectal cancer patients with isolated IGN recur-
rence using groin RT and subsequent chemotherapy. All
achieved local control in the groin region, although one
patient subsequently developed pelvic and distant metas-
tases. Mesko et al. [11] reported that the median survival
of rectal cancer patients (n = 4) with isolated IGN recur-
rence was significantly better than that of those (n = 9)
with non-isolated IGN recurrence (20 vs. 12 months from
IGN recurrence; p = 0.045). In a case series, Bardia et al.
[12] suggested that solitary IGN metastasis, either at pres-
entation or metachronous, may represent a distinct subset
of distal rectal cancer with a more favorable prognosiscompared with other metastatic rectal cancers. Graham
et al. [13] reported that isolated IGN recurrence developed
only in patients whose primary rectal tumor was located
within 3 cm of the anal verge and who had an earlier tumor
stage at presentation compared with those who developed
non-isolated IGN recurrence. All eight patients with iso-
lated IGN recurrence underwent groin dissection; six sur-
vived more than 2 years after. In the present study, salvage
therapy using concurrent CRT and/or surgical excision
yielded long-term control of recurrent disease in IGN (10
years in one and >5 years in two patients; Table 3). The iso-
lated IGN recurrence may be considered an oligometastatic
state, which is increasingly regarded as an adequate indica-
tion for curative-intent local RT [14]. Our group reported
favorable outcomes following definitive RT for solitary
para-aortic nodal metastasis from colorectal cancer [15]. If
isolated IGN recurrence represents the true recurrence risk
due to the existence of ACI, and salvage of this type of re-
currence is feasible, the wait-and-see policy in IGN basins
for rectal cancer with ACI could be supported.
Enlargement of the RT field to encompass the groin
region is associated with a variety of acute and late mor-
bidities, such as desquamation and fibrosis of the in-
guinal skin, wound and bowel complications, and edema
of the extremities and femoral neck fractures [6]. To
avoid these morbidities, omission of prophylactic in-
guinal irradiation is suggested for early-stage (cT1) anal
cancer, which shows a < 5% IGN failure rate when IGN
irradiation is eliminated [16-19]. However, innovative RT
technologies, including intensity-modulated RT and pro-
ton therapy, will reduce the exposure of normal organs
to radiation and accordingly the radiation-related morbid-
ities in the treatment of anorectal cancer [20]. Further-
more, identification of the disease characteristics linked to
an increased risk of developing IGN recurrence in
addition to ACI will assist in decisions regarding elective
IGN irradiation in the minority of patients who will bene-
fit from this treatment despite the potential for complica-
tions. Research in rectal cancer has included the sentinel
node procedure [21], serial acquisition of 18F-deoxyfluoro-
glucose positron emission tomography-CT [22], and the
study of histological tumor features at the distal front in-
vading the dentate line [23].
Conclusion
Although in the present study IGN recurrence from rectal
cancer developed more frequently in the presence of ACI,
the 5-year rate was 3.5% despite the fact that the IGN re-
gion was not irradiated. Isolated IGN recurrence occurred
only from rectal tumors with ACI and increased the IGN
recurrence rate of these rectal tumors; however, salvage of
isolated IGN recurrence appeared feasible. Our results in-
dicated that routine elective IGN irradiation is unneces-
sary for distal rectal cancer with ACI.
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